Hospital
Grant Memorial Hospital
Grant Memorial Hospital was paid $13.06M by Medicaid between Jan 2018 and Jun 2023, across 148 billing codes. Its largest line is 99284, emergency room visit (serious) — 28% of everything it billed.
33Billing provider infoGRANT MEMORIAL HOSPITAL
PETERSBURG, WV 26847
PETERSBURG, WV 26847
33aNPI1598763666assigned 07/12/2005
33bProvider typeMedicare Defined Swing Bed Hospital Unit
28Total paid$13.06M
24GClaims186,409
24DCodes billed148
24AFirst – last monthJan 2018 – Jun 2023
Compared with peers
Next to other Medicare Defined Swing Bed Hospital Unit providers in West Virginia
Rank by total paid#2 of 5
Median peer was paid$6.61M
This provider vs. median2.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 41,554 | $2.48M | |
| 2019 | 26,634 | $2.15M | |
| 2020 | 36,905 | $2.88M | |
| 2021 | 37,666 | $2.36M | |
| 2022 | 28,088 | $2.10M | |
| 2023 | 15,562 | $1.08M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 28% | 12,610 | 11,151 | $3.64M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.9% | 7,003 | 6,275 | $1.29M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.4% | 4,042 | 3,517 | $1.23M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.3% | 3,898 | 3,404 | $555K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.4% | 974 | 896 | $438K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.4% | 13,789 | 11,213 | $308K |
| 80053 | Comprehensive metabolic panel | 2.3% | 11,225 | 9,220 | $296K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.9% | 5,258 | 4,533 | $248K |
| 36415 | Collection of venous blood by venipuncture | 1.9% | 14,233 | 11,497 | $242K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.8% | 1,947 | 1,462 | $236K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.8% | 2,822 | 2,209 | $229K |
| 71045 | Radiologic examination, chest; single view | 1.7% | 4,583 | 3,866 | $220K |
136 more codes
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 1.6% | 2,245 | $203K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.5% | 1,441 | $194K |
| 81000 | 1.4% | 10,806 | $187K | |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.3% | 2,114 | $172K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.2% | 582 | $163K |
| 59025 | Fetal non-stress test | 1.1% | 1,281 | $144K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.1% | 2,701 | $140K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 933 | $127K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,224 | $119K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,706 | $115K |
| 80306 | <1% | 3,509 | $114K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 993 | $108K |
| G0378 | Hospital observation service, per hour | <1% | 602 | $102K |
| 93041 | <1% | 2,252 | $99K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,015 | $94K |
| 84484 | <1% | 3,207 | $85K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,168 | $81K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,498 | $77K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 589 | $69K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 624 | $68K |
| 87631 | <1% | 364 | $60K | |
| 81025 | <1% | 1,658 | $56K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,386 | $51K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,989 | $48K |
| 83690 | <1% | 1,787 | $48K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,143 | $47K |
| 86900 | <1% | 1,012 | $46K | |
| 86850 | <1% | 1,766 | $45K | |
| 85007 | <1% | 2,345 | $44K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 424 | $42K |
| 80061 | Lipid panel | <1% | 1,745 | $39K |
| 85730 | <1% | 1,508 | $35K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 774 | $35K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 774 | $35K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,237 | $34K |
| 85610 | <1% | 1,845 | $34K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 661 | $32K |
| 84439 | <1% | 1,222 | $32K | |
| 73564 | <1% | 387 | $30K | |
| 86901 | <1% | 940 | $30K | |
| 82550 | <1% | 926 | $28K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 920 | $27K |
| 83880 | <1% | 1,479 | $27K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,183 | $26K |
| J3490 | Unclassified drugs | <1% | 623 | $25K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,327 | $24K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 533 | $24K |
| 82947 | <1% | 1,541 | $23K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 85 | $22K |
| 87186 | <1% | 980 | $21K | |
| 87077 | <1% | 867 | $20K | |
| 87205 | <1% | 1,333 | $20K | |
| 86803 | <1% | 560 | $20K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 337 | $20K |
| 88142 | <1% | 348 | $19K | |
| 87040 | <1% | 954 | $19K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 250 | $18K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 367 | $18K |
| J2704 | Injection, propofol, 10 mg | <1% | 297 | $17K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 238 | $16K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 179 | $16K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 333 | $16K |
| 73030 | <1% | 269 | $15K | |
| 87653 | <1% | 382 | $15K | |
| 74018 | <1% | 286 | $15K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 16 | $15K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 345 | $14K |
| 82150 | <1% | 488 | $14K | |
| 73610 | <1% | 219 | $13K | |
| 87340 | <1% | 314 | $13K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 313 | $13K |
| 83605 | <1% | 710 | $13K | |
| 36600 | <1% | 185 | $13K | |
| 86592 | <1% | 413 | $12K | |
| 85027 | <1% | 1,585 | $12K | |
| 86762 | <1% | 255 | $12K | |
| 82805 | <1% | 186 | $11K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 239 | $11K |
| 87081 | <1% | 415 | $10K | |
| 94760 | <1% | 193 | $9K | |
| 73630 | <1% | 160 | $9K | |
| 80081 | <1% | 99 | $9K | |
| 82951 | <1% | 585 | $9K | |
| 84702 | <1% | 175 | $8K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 272 | $7K |
| 73110 | <1% | 88 | $6K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 41 | $6K |
| 73502 | <1% | 88 | $6K | |
| 85379 | <1% | 277 | $6K | |
| 83735 | <1% | 509 | $6K | |
| 82607 | <1% | 160 | $5K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 82 | $4K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 32 | $4K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 96 | $3K |
| 85651 | <1% | 136 | $3K | |
| 80076 | <1% | 242 | $3K | |
| 73130 | <1% | 54 | $3K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 14 | $3K |
| 84703 | <1% | 150 | $3K | |
| 96376 | <1% | 119 | $3K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 320 | $3K |
| 93971 | <1% | 15 | $3K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 51 | $2K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 14 | $2K |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 110 | $2K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 156 | $2K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 17 | $2K |
| 87420 | <1% | 32 | $2K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 13 | $2K |
| 76536 | <1% | 14 | $2K | |
| 51702 | <1% | 31 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 381 | $2K |
| 86140 | <1% | 43 | $1K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 83 | $1K |
| 72110 | <1% | 15 | $1K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 26 | $734.98 |
| 85018 | <1% | 33 | $707.59 | |
| 85014 | <1% | 33 | $707.58 | |
| 97162 | <1% | 12 | $688.53 | |
| 87076 | <1% | 22 | $603.08 | |
| 87280 | <1% | 21 | $532.98 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 15 | $531.47 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 13 | $508.32 |
| 82247 | <1% | 18 | $466.80 | |
| 82746 | <1% | 41 | $430.66 | |
| 84132 | <1% | 17 | $404.53 | |
| 82435 | <1% | 17 | $404.53 | |
| 84295 | <1% | 17 | $404.53 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 15 | $341.25 |
| 73140 | <1% | 14 | $328.87 | |
| 82728 | <1% | 12 | $209.99 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 15 | $173.86 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 13 | $110.94 |
| 83540 | <1% | 13 | $80.93 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 37 | $54.18 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 17 | $28.92 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMILVET, ROBERT (CEO)
| Provider | Location | Paid |
|---|---|---|
| Grant Memorial Hospital | Petersburg, WV | $133K |
| Grant Memorial Hospital | Petersburg, WV | $79K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.